BACE1 and frontotemporal dementia: Complementing neuroimaging approaches, biochemical markers have shown promise for differential diagnosis, with Saraceno et al. [25] identifying serum Beta-Secretase 1 (BACE1) activity as a potential biomarker that distinguishes AD from FTD, showing significantly elevated levels in AD patients compared to both FTD patients and healthy controls.